Quadrivalent RIV with 2018-2019 NH H3 strain

BIOLOGICAL2 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

Healthy VolunteersInfluenzaInfluenza Immunisation

Phase 1

Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age

CompletedNCT04144179

Sanofi Pasteur, a Sanofi CompanyInfluenza

Start: 2019-11-06End: 2020-02-24Updated: 2025-07-29

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

CompletedNCT04451954

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers, Influenza Immunisation

Start: 2020-07-02End: 2021-09-20Updated: 2025-09-17